This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Falck, R. S. Articles by Carlson, R. G. Search for Related Content PubMed PubMed Citation Articles by Falck, R. S. Articles by Carlson, R. G. Social Bookmarking                         What's this?

Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis

Department of Community Health, Boonshoft School of Medicine, Center for Interventions, Treatment & Addictions Research, Wright State University, Dayton, OH, USA, russel.falck{at}wright.edu

Jichuan Wang

Department of Community Health, Boonshoft School of Medicine, Center for Interventions, Treatment & Addictions Research, Wright State University, Dayton, OH, USA

Robert G. Carlson

Department of Community Health, Boonshoft School of Medicine, Center for Interventions, Treatment & Addictions Research, Wright State University, Dayton, OH, USA

Research suggests that methylenedioxymethamphetamine (MDMA)/`ecstasy' can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression. This longitudinal study used the Beck Depression Inventory (BDI-II) to assess depressive symptomatology every six months over a two-year period among a community sample of young adult MDMA/`ecstasy' users (n = 402). Multilevel growth modeling was used to analyze changes in BDI scores. Between baseline and 24 months, the mean BDI score declined from 9.8 to 7.7. Scores varied significantly across individuals at baseline and declined at a rate of 0.36 points every six months. Persons with higher baseline scores were more likely to have their scores decrease over time. Several factors were significantly associated with score levels, independent of time: gender — men's scores were lower than women's; ethnicity — whites' scores were lower than those of non-whites; education — persons with at least some university education had scores that were lower than those without any college experience; benzodiazepines — current users' scores were higher than non-users'; opioids — current users' scores were higher than non-users'; and cumulative ecstasy use — people who had used MDMA more than 50 times had scores that were higher than persons who had used the drug less often. The results reported here show low levels of depressive symptoms among a sample that, after 24 months, consisted of both current and former MDMA users. The low and declining mean scores suggest that for most people MDMA/`ecstasy' use does not result in long-term depressive symptomatology.

Key Words: MDMA • ecstasy • substance abuse • depressive symptomatology • depression • BDI • longitudinal analysis

Journal of Psychopharmacology, Vol. 22, No. 1, 47-54 (2008)
DOI: 10.1177/0269881107078293


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?